These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 28421991

  • 1. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Donges E, Staatz CE, Benham H, Kubler P, Hollingworth SA.
    Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY, Williams KM, Day RO.
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [Abstract] [Full Text] [Related]

  • 4. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G, Barner JC, Rascati K, Richards K.
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [Abstract] [Full Text] [Related]

  • 7. Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004.
    Chan V, Tett SE.
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):462-8. PubMed ID: 16700080
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.
    Gossen N, Jacob L, Kostev K.
    Rheumatol Int; 2016 Aug; 36(8):1113-8. PubMed ID: 26936261
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y, Desai RJ, Liu J, Choi NK, Kim SC.
    Arthritis Res Ther; 2017 Jul 05; 19(1):159. PubMed ID: 28679392
    [Abstract] [Full Text] [Related]

  • 13. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E, Fagerli KM, Mikkelsen K, Rødevand E, Lexberg A, Kalstad S, Uhlig T, Kvien TK.
    Ann Rheum Dis; 2014 Oct 05; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract] [Full Text] [Related]

  • 14. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D.
    Clin Exp Rheumatol; 2017 Oct 05; 35(4):579-585. PubMed ID: 28281458
    [Abstract] [Full Text] [Related]

  • 15. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan 05; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT, Dijkmans BA.
    Drugs; 2005 Jan 05; 65(5):661-94. PubMed ID: 15748099
    [Abstract] [Full Text] [Related]

  • 17. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S.
    Am J Med; 2015 May 05; 128(5):539.e7-17. PubMed ID: 25534420
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH.
    Ann Intern Med; 2009 Nov 03; 151(9):612-21. PubMed ID: 19884622
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.